Sequence Information

    • DRAMP ID

    • DRAMP18068

    • Name

    • hLF1-11(Human lactoferrin 1-11)

    • Sequence

    • GRRRRSVQWCA

    • Description

    • hLF1-11 was significantly more effective than the full length protein or the peptide representing the second cationic domain. As with other antimicrobial peptides, hLF1-11 shows poor antimicrobial activity under physiological conditions in vitro, but it is highly effective in vivo against infections due to a variety of microorganisms, including Gram negative and Gram positive bacteria and fungi. The objective is to develop hLF1-11 for the treatment of fungal and bacterial infections that develop during neutropenia that results from myeloablative therapy to prepare for a haematopoietic stem cell transplant(HSCT) formerly referred to as bone marrow transplant.

    • Activity

    • Antibacterial, Antifungal

    • Target Organism

      • In vivo,a dose-dependent bacteriocidal effect of intravenous administered peptide was observed in both immunocompetent and -compromised mice with a MRSA infection and hLF1-11 0.4–40µg/kg reduced 2 – 3 logs of bacterial counts in mice

    • Reference

      • Comparable efficacies of the antimicrobial peptide human lactoferrin 1–11 and gentamicin in a chronic methicillin-resistantStaphylococcus aureusosteomyelitis model. Antimicrob. Agents Chemother.(2005).(PMID: 15917544)
      • Human lactoferrin and peptides derived from its N terminus are highly effective against infections with antibiotic-resistant bacteria. Infect. Immun.(2001)(PMID: 11179314)
      • The high effective antimicrobial peptide hLF (1-11) may be given to (immunocompromised) mice with a multidrug resistant Staphylococcus aureusinfection by various routes. 45th Interscience Conference on Antimicrob. Agents Chemother.Washington DC, USA (2005)

Clinical Information

    • Medical use

    • Bacteraemia and fungal infections in immunocompromized haematopoetic stem cell transplant recipients

    • Company

    • AM-Pharma Holding BV

    • Stage of Development

    • Phase I-II

    • Comments

    • hLF1-11 has proved efficacious in animal models of osteomyelitis and other bacterial infections.Significant efficacy observed in Phase I trials; mechanism of action appears to be immunomodulatory rather than antibiotic.

    • Clinical Trials

    • NCT00430469
    • NCT00509834
    • NCT00509847
    • NCT00509938